Merck’s Enpatoran FDA Breakthrough Therapy Designation Granted for Cutaneous Lupus Treatment
Merck has secured an FDA Breakthrough Therapy designation for enpatoran, an investigational oral TLR7/8 inhibitor aiming to address the high unmet need in lupus patients suffering from active skin manifestations.
